Dual Incretin Revolution: Tirzepatide’s Mechanism And Clinical Impact in Obesity & Diabetes 2025-06-19
Tirzepatide, a dual GIP/GLP-1 receptor agonist, represents a breakthrough in obesity and type 2 diabetes treatment. This article explores its synergistic mechanism, superior clinical outcomes, and global market potential. It also highlights how Unibest supports global pharma companies with API sourcing, licensing, and regulatory services in the incretin drug space.
Read More